Vesalio has announced the appointment of Greg Cook as chief commercial officer (CCO).
The company have stated that Cook will be responsible for leading Vesalio’s commercial strategy, market development, sales, marketing, and commercial operations. A recent press release made by the company describes how Cook will play a key role in supporting Vesalio’s commercial expansion as the company continues advancing its thrombectomy platform across neurovascular, coronary, and peripheral vascular markets.
With more than 20 years of medical device experience, Cook most recently served as senior vice president of sales at Philips Image Guided Therapy Devices, where he led US commercialisation of the VeriSight intracardiac echocardiography platform. He previously led Philips’ cardiac lead management sales organisation.
“Greg brings the commercial leadership, market development expertise, and physician relationships that align with Vesalio’s strategic priorities,” said Steve Rybka, chief executive officer of Vesalio. “His experience building commercial organisations and introducing innovative technologies to treat vascular disease will be a valuable asset as we expand our thrombectomy platform, which uniquely addresses the full range of challenges in clot capture and removal.”
“I am excited to join Vesalio and work alongside a talented team committed to advancing thrombectomy management,” said Cook. “Vesalio’s commitment to clinical innovation and physician partnership creates a strong foundation for continued growth, and I look forward to expanding access to technologies that improve patient outcomes.”
